Full Press Release Details
Hyperion DeFi Provides Corporate Update and
Reports Second Quarter 2025 Financial Results
Successfully establishes cryptocurrency treasury
reserve focused on the HYPE token and becomes the first
publicly listed U.S. company to implement DeFi strategies on Hyperliquid blockchain
Accumulates more than 1.5 million HYPE to date
and establishes co-branded validator with Kinetiq
Reiterates FDA registration of the Optejet User
Filled Device (UFD) remains on track for September 2025
LAGUNA HILLS, CA-August 13, 2025-Hyperion
DeFi, Inc. (NASDAQ: HYPD), the first publicly-listed U.S. company to implement DeFi strategies on its treasury of HYPE, the native
token of the Hyperliquid protocol, and a pioneer in ophthalmic digital technologies, today provided a corporate update and announced financial
results for the second quarter ended June 30th, 2025.
Second Quarter 2025 and Recent Achievements:
Michael Rowe, Chief Executive Officer of Hyperion
DeFi, stated, "The transformation that we have undergone over the past two months has been nothing short of remarkable, and I could
not be more excited to be part of a pioneering organization that is leading the way in leveraging the accelerating adoption of digital
currencies to create long-term value for shareholders. Hyperion DeFi blends the benefits of a regulated public company with opportunities
only available through decentralized finance, and our focus on HYPE and the Hyperliquid ecosystem truly sets us apart as more and more
companies adopt various digital treasury asset strategies."
"At the same time, we continue to work tirelessly
to complete the remaining development steps in support of FDA registration of the Optejet User Filled Device, which we anticipate next
month. We are pleased with the level of interest we are seeing from potential development partners and view the Optejet UFD as an additional
Hyunsu Jung, Chief Investment Officer of Hyperion
DeFi, added, "Our focus here at Hyperion DeFi is to provide investors with the unique opportunity to partake in the value created
by our operations in staking, capital deployment in DeFi, and other unique Hyperliquid growth initiatives. Accumulating more than 1.5
million HYPE was just the beginning - I am very excited for what the future holds for our company and our shareholders as we begin to
deploy our other revenue-generating products. We expect these strategies to create powerful tailwinds for Hyperliquid's continued
growth and adoption, which should in turn benefit the performance of the HYPE token that we are continuing to accumulate in our treasury."
Second Quarter 2025 Financial Review
For the second quarter of 2025, net loss attributable
to common stockholders was $8.8 million, or $2.50 per share. This compares to a net loss of $11.1 million, or $16.65 per share, for the
second quarter of 2024.
Research and development expenses for the
second quarter of 2025 totaled $0.7 million, a decrease of $3.9 million, or 85%, compared to $4.6 million recorded for the second quarter
of 2024. The decrease was driven primarily by a reduction in headcount in the fourth quarter of 2024 after the termination of the Company's
CHAPERONE study in November 2024.
and administrative expenses for the second quarter of 2025 totaled $7.7 million, an increase of $3.9 million, or 104%, compared to $3.8
million recorded for the second quarter of 2024. The increase was due to a one-time non-cash stock-based compensation inducement grant
given to a newly hired executive, as well as higher professional fees as a result of our assessment of strategic options earlier
this year concluding with our $50 million financing and establishment of the treasury strategy in June. These costs were offset by decreases
in costs resulting from initiatives that we implemented beginning late last year with the termination of the CHAPERONE study and commercial
operations in November 2024.
As of June 30, 2025, the Company's
unrestricted cash and cash equivalents were $7.5 million, as compared to $2.1 million in unrestricted and restricted cash as of December 31,
About Hyperion DeFi, Inc.
Hyperion DeFi, Inc. is the first U.S. publicly
listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE. The Company is focused on providing
its shareholders with simplified access to the Hyperliquid ecosystem, one of the fastest growing, highest revenue-generating blockchains
in the world. Shareholders benefit from a gradually compounding exposure to HYPE, both from its native staking yield and additional revenues
generated from its unique on-chain utility.
Hyperion DeFi is also developing its proprietary
Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and
lens rewetting products. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety
and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment
compliance and better outcomes for patients and providers.
For more information, please visit Hyperiondefi.com.
Forward Looking Statements
Except for historical
information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking
statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or
any other statements, our future activities or other future events or conditions, including the estimated market opportunities for our
platform technology, the viability of, and risks associated with, our cryptocurrency treasury strategy, the clinical trials that may be
necessary in connection with the clearance of the Optejet UFD, and the timing for sales growth of our approved products. These statements
are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These
statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore,
actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking
statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission.
In addition, such statements
could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited
to, the potential advantages of our products, and platform technology; the rate and degree of market acceptance and clinical utility of
our products; our estimates regarding the potential market opportunity for our products; reliance on third parties to develop and commercialize
our products; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing
capabilities and strategies for our products; intellectual property risks; changes in legal, regulatory, legislative and geopolitical
environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products
and product candidates; our competitive position; our ability to raise additional funds to maintain our business operations and to make
payments on our debt obligations as and when necessary; and the risks of our cryptocurrency strategy as detailed in our Current Report
on Form 8-K filed on June 27, 2025.
statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Hyperion
DeFi does not undertake any obligation to update any forward-looking statements.
DeFi Investor Contact:
LifeSci Advisors, LLC
Condensed Balance Sheets
| June 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | 7,532,291 | $ | 2,121,463 | ||||
| Deposit to be refunded | 888,000 | - | ||||||
| Prepaid expenses and other current assets | 967,006 | 645,736 | ||||||
| Total Current Assets | 9,387,297 | 2,767,199 | ||||||
| HYPE digital tokens | 45,500,000 | - | ||||||
| Property and equipment, net | 22,959 | - | ||||||
| Security deposits, non-current | 182,200 | 182,200 | ||||||
| Operating lease right-of-use asset | 567,180 | 718,360 | ||||||
| Total Assets | $ | 55,659,636 | $ | 3,667,759 | ||||
| Liabilities and Stockholders' Equity (Deficiency) | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 901,594 | $ | 1,954,681 | ||||
| Accrued inducement grant | 5,190,000 | - | ||||||
| Accrued former licensor obligations | 2,245,087 | 2,245,087 | ||||||
| Accrued expenses and other current liabilities | 1,496,804 | 1,322,674 | ||||||
| Operating lease liabilities - current portion | 477,609 | 575,163 | ||||||
| Notes payable - current portion, net of debt discount of $0 and $527,870 as of June 30, 2025 and December 31, 2024, respectively | - | 5,212,532 | ||||||
| Convertible notes payable - current portion, net of debt discount of $0 and $263,930 as of June 30, 2025 and December 31, 2024, respectively | - | 4,736,070 | ||||||
| Total Current Liabilities | 10,311,094 | 16,046,207 | ||||||
| Notes payable - non-current portion, net of debt discount of $654,151 and $0 as of June 30, 2025 and December 31, 2024, respectively | 7,516,735 | - | ||||||
| Operating lease liabilities - non-current portion | 473,241 | 717,504 | ||||||
| Total Liabilities | 18,301,070 | 16,763,711 | ||||||
| Stockholders' Equity (Deficiency): | ||||||||
| Preferred stock, $0.0001 par value, 6,000,000 shares authorized; Series A Non-Voting Convertible Preferred Stock, 5,435,898 shares designated, and 5,435,897 and 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | 544 | - | ||||||
| Common stock, $0.0001 par value, 300,000,000 shares authorized; 4,854,827 and 1,506,369 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | 485 | 151 | ||||||
| Additional paid-in capital | 244,841,981 | 182,213,889 | ||||||
| Accumulated deficit | (207,484,444 | ) | (195,309,992 | ) | ||||
| Total Stockholders' Equity (Deficiency) | 37,358,566 | (13,095,952 | ) | |||||
| Total Liabilities and Stockholders' Equity (Deficiency) | $ | 55,659,636 | $ | 3,667,759 |
Condensed Statement of Operations
| For the Three Months Ended | For the Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Operating Income | ||||||||||||||||
| Revenue | $ | - | 22,625 | $ | 14,720 | $ | 27,618 | |||||||||
| Cost of revenue | - | (490,361 | ) | (48 | ) | (693,388 | ) | |||||||||
| Gross Profit (Loss) | - | (467,736 | ) | 14,672 | (665,770 | ) | ||||||||||
| Operating Expenses: | ||||||||||||||||
| Research and development | 674,578 | 4,597,173 | 1,347,621 | 9,028,774 | ||||||||||||
| Selling, general and administrative | 7,678,704 | 3,758,835 | 10,051,026 | 7,396,024 | ||||||||||||
| Reacquisition of license rights | - | 2,864,600 | - | 4,864,600 | ||||||||||||
| Total Operating Expenses | 8,353,282 | 11,220,608 | 11,398,647 | 21,289,398 | ||||||||||||
| Loss From Operations | (8,353,282 | ) | (11,688,344 | ) | (11,383,975 | ) | (21,955,168 | ) | ||||||||
| Other Income (Expense): | ||||||||||||||||
| Other income (expense), net | 168,840 | 2,980 | 172,527 | (94,578 | ) | |||||||||||
| Gain on debt extinguishment | - | - | 89,623 | - | ||||||||||||
| Change in fair value of equity consideration payable | - | 1,240,800 | - | 1,240,800 | ||||||||||||
| Interest expense | (528,410 | ) | (674,001 | ) | (1,109,909 | ) | (1,352,659 | ) | ||||||||
| Interest income | 21,933 | 64,866 | 57,282 | 185,805 | ||||||||||||
| Total Other Income (Expense) | (337,637 | ) | 634,645 | (790,477 | ) | (20,632 | ) | |||||||||
| Net Loss | (8,690,919 | ) | (11,053,699 | ) | (12,174,452 | ) | (21,975,800 | ) | ||||||||
| Dividend to preferred stockholders | (97,167 | ) | - | (97,167 | ) | - | ||||||||||
| Net Loss Attributable to Common Stockholders | $ | (8,788,086 | ) | $ | (11,053,699 | ) | $ | (12,271,619 | ) | $ | (21,975,800 | ) | ||||
| Net Loss Per Share - Basic and Diluted | $ | (2.50 | ) | $ | (16.65 | ) | $ | (4.29 | ) | $ | (35.26 | ) | ||||
| Weighted Average Shares Outstanding - Basic and Diluted | 3,518,906 | 664,022 | 2,857,596 | 623,303 |